<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04208594</url>
  </required_header>
  <id_info>
    <org_study_id>123</org_study_id>
    <nct_id>NCT04208594</nct_id>
  </id_info>
  <brief_title>Efficacy of Ivabradine Versus Propranolol Premedication During Hypotensive Anesthesia in Endoscopic Sinus Surgery</brief_title>
  <official_title>Efficacy of Ivabradine Versus Propranolol Premedication During Hypotensive Anesthesia in Endoscopic Sinus Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      50 Patients, aged from 18 to 39 years, ASA physical status I and II, undergoing endoscopic&#xD;
      sinus surgery will be enrolled in the study.The patients will be randomly allocated by simple&#xD;
      randomization using a computer programme into two groups by closed envelope technique (having&#xD;
      25 patients in each group): GROUP (P): will receive oral propranolol (INDERAL® -propranolol&#xD;
      hydrochloride Ph. Eur. 10mg manufactured by AstraZeneca Egypt under license of AstraZeneca&#xD;
      UK), 10 mg one tablet at 8:00 pm in the evening before the day of the surgery and one 10 mg&#xD;
      tablet one hour before the induction of anesthesia.&#xD;
&#xD;
      GROUP (I): will receive oral ivabradine (Procoralan® 5mg manufactured by Servier&#xD;
      laboratories, France), 5 mg one tablet at 8:00 pm in the evening before the day of the&#xD;
      surgery and one 5 mg tablet one hour before the induction of anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of the work To compare efficacy of oral premedication with ivabradine versus propranolol&#xD;
      before hypotensive anesthesia with nitroglycerin during endoscopic sinus surgery on reduction&#xD;
      of reflex tachycardia.&#xD;
&#xD;
      Secondary aim:&#xD;
&#xD;
        -  Compare the safety and incidence of side effects between both drugs.&#xD;
&#xD;
        -  Compare the amount of nitroglycerin used, and blood loss between both drugs during&#xD;
           endoscopic sinus surgery.&#xD;
&#xD;
      Patients and methods This study will be conducted in the Department of Anesthesia, ENT&#xD;
      operating theater, Alexandria University Hospitals after being approved by the Departmental&#xD;
      Research and Ethical Committee, and after obtaining informed consents from all patients.&#xD;
&#xD;
      50 Patients, aged from 18 to 39 years, ASA physical status I and II, undergoing endoscopic&#xD;
      sinus surgery will be enrolled in the study.&#xD;
&#xD;
      Exclusion Criteria:&#xD;
&#xD;
        -  Patients with cardiovascular disease (hypertension, congestive heart failure, and&#xD;
           coronary artery disease).&#xD;
&#xD;
        -  Patients on beta-blockers.&#xD;
&#xD;
        -  Patients with the base line heart rate&lt;60 beats per minute.&#xD;
&#xD;
        -  Patients with diabetes mellitus (DM).&#xD;
&#xD;
        -  Cerebrovascular insufficiency.&#xD;
&#xD;
        -  Coagulation defects.&#xD;
&#xD;
        -  History of renal or hepatic insufficiency.&#xD;
&#xD;
        -  Hypersensitivity to the study drugs.&#xD;
&#xD;
        -  Patients with history of bronchial asthma&#xD;
&#xD;
      The patients will be randomly allocated by simple randomization using a computer programme&#xD;
      into two groups by closed envelope technique (having 25 patients in each group):&#xD;
&#xD;
      GROUP (P): will receive oral propranolol (INDERAL® -propranolol hydrochloride Ph. Eur. 10mg&#xD;
      manufactured by AstraZeneca Egypt under license of AstraZeneca UK), 10 mg one tablet at 8:00&#xD;
      pm in the evening before the day of the surgery and one 10 mg tablet one hour before the&#xD;
      induction of anesthesia.&#xD;
&#xD;
      GROUP (I): will receive oral ivabradine (Procoralan® 5mg manufactured by Servier&#xD;
      laboratories, France), 5 mg one tablet at 8:00 pm in the evening before the day of the&#xD;
      surgery and one 5 mg tablet one hour before the induction of anesthesia.&#xD;
&#xD;
      Preoperative screening of all patients will include:&#xD;
&#xD;
        1. Demographic data (age, sex).&#xD;
&#xD;
        2. Detailed medical history.&#xD;
&#xD;
        3. Complete physical examination.&#xD;
&#xD;
        4. Routine laboratory investigations:&#xD;
&#xD;
             -  Complete blood picture.&#xD;
&#xD;
             -  Bleeding time and coagulation time.&#xD;
&#xD;
             -  Prothrombin time and activated partial thromboplastin time.&#xD;
&#xD;
             -  Liver enzymes: alanine aminotransferase (ALT) and aspartate aminotransferase (AST).&#xD;
&#xD;
             -  Serum bilirubin (total and direct).&#xD;
&#xD;
             -  Blood urea and serum creatinine.&#xD;
&#xD;
             -  Fasting blood sugar.&#xD;
&#xD;
        5. Chest X-ray.&#xD;
&#xD;
        6. Standard 12 leads electrocardiogram.&#xD;
&#xD;
      Anesthesia:&#xD;
&#xD;
      • All patients will receive the same anesthetic technique.&#xD;
&#xD;
        -  Premedication will be standardized for all patients and consists of oral diazepam 5 mg&#xD;
           the night before surgery.&#xD;
&#xD;
        -  On arrival to operating room, intravenous line will be cited and lactated ringer&#xD;
           solution will be infused 4-6 ml/kg/h.&#xD;
&#xD;
        -  Before induction of general anesthesia (GA), all patients will be monitored with:&#xD;
&#xD;
        -  None-invasive blood pressure (NIBP).&#xD;
&#xD;
        -  Electrocardiograph (ECG).&#xD;
&#xD;
        -  Pulse oximeter (SpO2).&#xD;
&#xD;
        -  After induction of GA, all patients will be monitored with:&#xD;
&#xD;
        -  Capnography for end-tidal CO2 (ETCO2).&#xD;
&#xD;
        -  Radial artery cannula (G20) for intra-arterial blood pressure monitoring after&#xD;
           performing Allen's test.&#xD;
&#xD;
        -  Peripheral nerve stimulator (PNS) will be applied on the ulnar nerve for neuromuscular&#xD;
           blockade.&#xD;
&#xD;
      Induction and maintenance of anesthesia:&#xD;
&#xD;
        -  Anesthesia Will be induced with propofol 2mg/kg iv, fentanyl 1 μg/kg iv and&#xD;
           cisatracurium besylate 0.15 mg/kg iv, when TOF count showed disappearance of T1 (0/4)&#xD;
           endotracheal intubation with appropriate size will be accomplished and lungs will be&#xD;
           mechanically ventilated to maintain the ETCO2 30-35 mmHg.&#xD;
&#xD;
        -  Anesthesia will be maintained with inspired isoflurane 1.5 % and cisatracurium besylate&#xD;
           top up doses 0.03 mg/kg/30 min will be given guided with TOF count aiming to keep it as&#xD;
           1/4. Airway will be secured by oro-pharyngeal packing and patients will be positioned&#xD;
           supine with head up 30°. Dexamethasone 0.2 mg/kg and metoclopramide 10 mg slowly iv will&#xD;
           be given as emesis prophylaxis.&#xD;
&#xD;
        -  Deliberate hypotension will be induced until completion of the main surgical procedures&#xD;
           to achieve a MAP within the target range of 55-65 mm Hg (approximately 30% below a&#xD;
           patient's usual MAP), nitroglycerin (1mg/ml) with a dose range 5-20 mcg/min will be&#xD;
           added if needed.&#xD;
&#xD;
        -  All patients will be operated upon by the same surgical team.&#xD;
&#xD;
        -  Bleeding in the surgical field and the quality of the visibility will be assessed&#xD;
           subjectively by the surgeon who will be blinded to the infused drug using 6 points scale&#xD;
           adapted by Boezaart et al.(25):&#xD;
&#xD;
        -  0= no bleeding.&#xD;
&#xD;
        -  1= slight bleeding so blood evacuation not necessary.&#xD;
&#xD;
        -  2= slight bleeding so sometimes blood has to be evacuated.&#xD;
&#xD;
        -  3= low bleeding so blood has to be often evacuated and operative field is visible for&#xD;
           some seconds after evacuation.&#xD;
&#xD;
        -  4= average bleeding so blood has to be often evacuated, and operative field is visible&#xD;
           only right after evacuation.&#xD;
&#xD;
        -  5= high bleeding so constant blood evacuation is needed, sometimes bleeding exceeds&#xD;
           evacuation and surgery is hardly possible.&#xD;
&#xD;
      The 1st assessment will be 30 min after the beginning of surgery and then every 30 min till&#xD;
      the end of surgery.&#xD;
&#xD;
        -  As an objective method, the volume of fluid aspirated from the surgical field during&#xD;
           surgery will be also measured.&#xD;
&#xD;
        -  When blood loss exceed 300 mL, 6% hydroxyethyl starch solutions (Voluven, Fresinius&#xD;
           Kabi, Bad Homberg, Germany) will be administered at a 1:1 ratio, and if hematocrit is&#xD;
           &lt;27%, a transfusion will be initiated .&#xD;
&#xD;
        -  Hypotension (MAP&lt;55 mm Hg) will be treated with ephedrine 15 mg intravenous.&#xD;
&#xD;
        -  Bradycardia (HR˂ 50) will be recorded and managed with atropine 0.02mg/kg.&#xD;
&#xD;
        -  With termination of surgery, isoflurane will be discontinued, the oropharyngeal pack&#xD;
           will be removed and the oropharynx will be suctioned under direct vision using the rigid&#xD;
           laryngoscope. The residual cisatracurium will be reversed with neostigmine 0.05 mg/kg iv&#xD;
           and atropine 0.02 mg/kg iv when the TOF count is 2/4, trachea will be extubated once the&#xD;
           patients showed eye opening and purposeful movement and then patients will be&#xD;
           transferred to PACU where BP, SpO2 and ECG will be monitored. O2 supplementation will be&#xD;
           provided via face mask.&#xD;
&#xD;
      Measurements:&#xD;
&#xD;
      The following parameters will be measured and will be statistically analyzed between the two&#xD;
      studied groups:&#xD;
&#xD;
        1. Demographic data (age and sex).&#xD;
&#xD;
        2. Hemodynamic variables:&#xD;
&#xD;
             -  Mean arterial blood pressure (MABP) in mmHg by invasive monitoring using GE monitor&#xD;
                .&#xD;
&#xD;
             -  Heart rate: (beats / minute) using GE monitor.&#xD;
&#xD;
           Time Points for Hemodynamic Parameter Measurements:&#xD;
&#xD;
             -  Baseline before induction of anesthesia.&#xD;
&#xD;
             -  Before starting the infusion of NTG (baseline)&#xD;
&#xD;
             -  5 minutes after initiation of NTG&#xD;
&#xD;
             -  Every 30 min throughout deliberate hypotension till termination of NTG infusion.&#xD;
&#xD;
             -  5 minutes after the end of deliberate hypotension&#xD;
&#xD;
             -  Immediately after extubation in the operating room&#xD;
&#xD;
             -  60 min after extubation in the PACU&#xD;
&#xD;
        3. The amount of nitroglycerin used:&#xD;
&#xD;
             -  Duration of DH (min(&#xD;
&#xD;
             -  NTG amounts during DH (μg/kg/min).&#xD;
&#xD;
        4. Blood loss and need for blood transfusion:&#xD;
&#xD;
             -  Intraoperative bleeding (mL).&#xD;
&#xD;
             -  Intraoperative autologous blood transfusion (units of packed RBCs).&#xD;
&#xD;
        5. Total urine output (mL).&#xD;
&#xD;
        6. Laboratory investigations:&#xD;
&#xD;
             -  Random blood sugar (RBS)&#xD;
&#xD;
             -  Serum lactate level. Both will be measured immediately after induction of&#xD;
                anesthesia, and after discontinuation of deliberate hypotension (NTG infusion).&#xD;
&#xD;
        7. Duration of surgery (the time from start of surgical intervention till its end) (min.).&#xD;
&#xD;
        8. Patients administered ephedrine during DH (n).&#xD;
&#xD;
        9. Events of bradycardia (frequency).&#xD;
&#xD;
       10. Complications need intervention such as bronchospasm, laryngospasm, or vomiting will be&#xD;
           recorded and managed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2019</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemodynamic changes :</measure>
    <time_frame>Baseline before induction of anesthesia. - Every 30 min throughout deliberate hypotension till termination of NTG infusion. - 5 minutes after the end of deliberate hypote</time_frame>
    <description>Mean arterial blood pressure (MABP) in mmHg by invasive monitoring using GE monitor .&#xD;
• Heart rate: (beats / minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>amount of Blood loss</measure>
    <time_frame>the procedure time</time_frame>
    <description>Intraoperative bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of Complications</measure>
    <time_frame>the procedure time</time_frame>
    <description>Complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ivabradine</condition>
  <condition>Propranolol</condition>
  <condition>Hypotensive Anesthesia</condition>
  <arm_group>
    <arm_group_label>GROUP (P):</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will receive oral propranolol (INDERAL® -propranolol hydrochloride Ph. Eur. 10mg manufactured by AstraZeneca Egypt under license of AstraZeneca UK), 10 mg one tablet at 8:00 pm in the evening before the day of the surgery and one 10 mg tablet one hour before the induction of anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP (I):</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will receive oral ivabradine (Procoralan® 5mg manufactured by Servier laboratories, France), 5 mg one tablet at 8:00 pm in the evening before the day of the surgery and one 5 mg tablet one hour before the induction of anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>comparing between both drugs for the effect of hypotensive anesthesia</description>
    <arm_group_label>GROUP (I):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>comparing between both drugs for the effect of hypotensive anesthesia</description>
    <arm_group_label>GROUP (P):</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA physical status I and II, undergoing endoscopic sinus surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with cardiovascular disease (hypertension, congestive heart failure, and&#xD;
             coronary artery disease).&#xD;
&#xD;
          -  Patients on beta-blockers.&#xD;
&#xD;
          -  Patients with the base line heart rate&lt;60 beats per minute.&#xD;
&#xD;
          -  Patients with diabetes mellitus (DM).&#xD;
&#xD;
          -  Cerebrovascular insufficiency.&#xD;
&#xD;
          -  Coagulation defects.&#xD;
&#xD;
          -  History of renal or hepatic insufficiency.&#xD;
&#xD;
          -  Hypersensitivity to the study drugs.&#xD;
&#xD;
          -  Patients with history of bronchial asthma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alexandria university</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yasser mh osman, prof</last_name>
      <phone>01006357996</phone>
      <phone_ext>02</phone_ext>
      <email>yasseralx@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Yasser mh Osman, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ayman kalefa, lecturer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Yasser Mohamed Mohamed Osman</investigator_full_name>
    <investigator_title>assistant professor of anesthesia Alexandria university</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

